Abstract: Certain embodiments of the invention provide a method of promoting T lymphocyte proliferation, comprising contacting in vitro, ex vivo or in vivo a population of cells comprising T lymphocytes with an effective amount of N1-hexyl-N5-benzyl biguanide (HBB), or a pharmaceutically acceptable salt thereof, wherein contact with HBB, or a pharmaceutically acceptable salt thereof, causes proliferation of the T lymphocytes.

Abstract: A method for generating source code objects based on a unified system model designed using a standard unified modeling tool, data in the form of a data model constructed using a logical modeling tool and unified model translator with said data being retrieved from legacy databases and translated into the data model for operation by the system, and a system search query generated by a system user.

Abstract: Systems and methods are disclosed herein that enable computer-implemented modeling of lymphocyte differentiation and developmental processes. Cell-based models and methods for simulating natural and transgenic lymphocyte differentiation are also disclosed. In some embodiments, systems and methods are provided for cell-centric simulation of lymphocyte differentiation with accommodating virtual thymic and/or bone marrow environment feedback. In one embodiment, a computer-implemented method of modeling lymphocyte differentiation can include receiving configurable simulation information and initializing an ontogeny engine to an initial step boundary in accordance with the configurable simulation information. The method can also include advancing the ontogeny engine, until a halting condition is encountered, from a current step boundary to a next step boundary in accordance with the configurable simulation information and the current step boundary.

Abstract: Coumermycin analogs of general formula I: wherein X, a linking group, is selected from the group consisting of alkyl, aryl, diaryl, substituted alkyl, substituted aryl, alkyl with hereroatoms in the chain, heteroaryl, cyclic and bicyclic alkyl, and a combination of alkyl, aryl and heteroaryl substituents. The compounds are suitable for use as chemical dimerizers of chimeric proteins.

Abstract: Coumermycin analogs of general formula I: 1

Abstract: Novel compositions and methods for inhibiting cytokine-induced intracellular activation of STAT family transcription factors by binding to the transcription factors and inhibiting the transcriptional activity of the factors are disclosed. The method comprises introducing into a cell an effective amount of a peptide or derivative thereof, in which the peptide contains a sequence that is derived from a receptor for the cytokine, but with a tyrosine residue being phosphorylated. The compositions comprise isolated peptides or derivatives thereof in which the peptide contains an amino acid sequence derived from a receptor for a cytokine but with a tyrosine residue phosphorylated. A method for identifying derivatives of the isolated peptides comprising detecting the inhibition of the binding of said peptide to a STAT family transcription factor by said derivative is also provided.

Abstract: Novel compositions and methods that result in the inactivation of IFN.gamma. inducible transcription factors by binding to the transcription factor in the cell and inhibiting the transcriptional activity of the factors are disclosed. The composition comprises an isolated peptide that contains the amino acid sequence Xaa.sub.1 -Asp-Xaa.sub.2 -Xaa.sub.3 -His SEQ ID No. 1 where Xaa.sub.1 is phosphorylated tyrosine and Xaa.sub.2 and Xaa.sub.3 are any amino acid, or derivatives and functional equivalents thereof, that is capable of specifically binding to the p91 family of IFN.gamma. inducible transcription factors in a cell. A method for inhibiting the intracellular activation of a transcription factor by introducing into a cell an effective amount of a peptide that contains the 5 amino acid sequence described or a derivative thereof, which specifically binds to a transcription factor in the cell is also provided.

Abstract: Novel compositions and methods that result in the inactivation of IFN.gamma. inducible transcription factors by binding to the transcription factor in the cell and inhibiting the transcriptional activity of the factors are disclosed. The composition comprises an isolated peptide that contains the amino acid sequence Xaa.sub.1 -Asp-Xaa.sub.2 -Xaa.sub.3 -His where Xaa.sub.1 is phosphorylated tyrosine and Xaa.sub.2 and Xaa.sub.3 are any amino acid, or derivatives and functional equivalents thereof, that is capable of specifically binding to the p91 family of IFN.gamma. inducible transcription factors in a cell. A method for inhibiting the intracellular activation of a transcription factor by introducing into a cell an effective amount of a peptide that contains the 5 amino acid sequence described or a derivative thereof, which specifically binds to a transcription factor in the cell is also provided.